Investors2022-06-24T07:05:07+00:00

Investor Information

Stock Chart

View Listing

Investor News

  • PSYENCE GROUP ANNOUNCES DTC ELIGIBILITY APPROVAL IN THE U.S.

Psyence Group Announces DTC Eligibility Approval in the U.S

February 9, 2022|

TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).

  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

January 21, 2022|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

Investor News

Psyence Group Announces Private Placement

Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).

Why Psyence?

Focused on natural psychedelics

    • Psyence Production:Producing natural psilocybin at our federally licensed facility ISO22000 certified facility
    • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences

Operational

      • In 2020, Psyence was granted a licence to cultivate and export psilocybin mushrooms. Our ISO22000 state-of-the-art facility is operational

International expertise in palliative medicine and science

      • Our scientific and medical team includes Dr. Clive Ward-Able, a pharmaceutical industry veteran with significant experience in the commercialization of a pharmaceutical product and direct involvement in designing and conducting clinical trials. Dr. Amza Ali, an internationally recognized neurologist, and Dr. Justin Grant, a leader in drug development.
      • Psyence CEO Dr. Neil Maresky is physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.

Extensive networks and partnerships

      • We are building partnerships with a network of institutions and companies including:
      • Government research centres
      • University hospitals and research centres
      • Regulatory stakeholders
      • Non-governmental organizations (NGOs)

Extensive capital markets/business building experience

      • Experienced global executive team
      • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

An IP portfolio in cultivation and therapeutic products

      •  A mix of certified spores under cultivation
      • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development

Functional mushroom brand

      • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP

Why Psyence?

Focused on natural psychedelics

      • Psyence Production:Producing natural psilocybin at our federally licensed facility ISO22000 certified facility
      • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences

Operational

        • In 2020, Psyence was granted a licence to cultivate and export psilocybin mushrooms. Our ISO22000 state-of-the-art facility is operational

Extensive capital markets/business building experience

        • Experienced global executive team
        • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

        • Our scientific and medical team includes Dr. Clive Ward-Able, a pharmaceutical industry veteran with significant experience in the commercialization of a pharmaceutical product and direct involvement in designing and conducting clinical trials. Dr. Amza Ali, an internationally recognized neurologist, and Dr. Justin Grant, a leader in drug development.
        • Psyence CEO Dr. Neil Maresky is physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.

Extensive networks and partnerships

        • We are building partnerships with a network of institutions and companies including:
        • Government research centres
        • University hospitals and research centres
        • Regulatory stakeholders
        • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

        •  A mix of certified spores under cultivation
        • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development

Functional mushroom brand

        • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Investor Sign-Up

Please enter your details below to receive investor updates on Psyence Group


By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 200 Bay Street, Toronto, ON, M5J2J1, https://www.psyence.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP
Go to Top